MHRA backs Merck’s MET inhibitor Tepmetko

Pharma Times

13 October 2021 - The UK MHRA has conditonally authorised Merck’s MET inhibitor Tepmetko (tepotinib) for the treatment of certain non-small-cell lung cancer patients.

The conditional marketing authorisation opens access to Tepmetko treatment for adult patients with advanced non-small-cell lung cancer harbouring mesenchymal-epithelial transition factor gene exon 14 skipping alterations.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , England , Medicine